Burden of medication in patients with lung neuroendocrine tumors (NETs) in a US real-world setting

#4190

Introduction: Real-world evidence on patients with lung NETs, specifically on comorbidities and the prevalence of carcinoid syndrome (CS), is lacking.

Aim(s): To investigate the burden of concomitant, non-NETs medications on patients with lung NETs.

Materials and methods: Adults with lung NETs (ICD-10-CM code), with and without CS, with ≥1 inpatient or ≥2 outpatient claims and who initiated first-line treatment (index date) were identified from the US MarketScan database (study period, Jan 1, 2016 – Dec 31, 2022) and matched (age, sex, insurance type) with four patients without cancer (reference group). Frequency of comorbidities (≥1 diagnosis claim) was calculated. At 3 months (0–90 days) post index date, frequency of medications used was compared (Chi-squared test).

Conference:

Presenting Author:

Authors: Starr J, Houchard A, Pommie C, Ribeiro-Oliveira Jr A, Chan J,

Keywords: lung, neuroendocrine tumor, concomitant medication, costs,